NovoCure Limited(NVCR) Stock Research - Grey Stern Research

NovoCure Limited (NVCR) Stock Analysis

$26.60 (-9.00%)

NVCR Financial Performance


Use the table below to view NovoCure Limited's financial profile. This data is gathers from the latest available financial statements. Annual data is taken from the trailing 12 months of statements. All numbers are reported in US Dollars and so any foreign currencies are converted to USD so comparison's can be done.

Based on Financial Statements from Q3 - 2024

Metric Value Ranking among Peers
Price $26.60 -
52 Week Low $11.66 -
52 Week High $32.60 -
Market Cap $2.9 Billion 9/15
Gross Margin 77% 6/15
Profit Margin -20% 14/15
EBITDA margin -21% 14/15
Q3 - 2024 Revenue $155.1 Million 10/15
Q3 - 2024 Earnings -$30.6 Million 14/15
Q3 - 2024 Free Cash Flow -$307,000 Million 12/15
Trailing 4 Quarters Revenue $577.7 Million 10/15
Trailing 4 Quarters Earnings -$149.8 Million 14/15
Quarterly Earnings Growth 38% 9/15
Annual Earnings Growth 32% 7/15
Quarterly Revenue Growth 22% 5/15
Annual Revenue Growth 14% 6/15
Cash On Hand $0 15/15
Short Term Debt $86.4 Million 1/15
Long Term Debt $0 14/15

NovoCure Limited Financial Metrics


Financial metrics are a set of useful numbers that can give key performance indicators of a company. The various metrics can include information about profitability, growth, and debt load. When combined and use properly they can tell an analyst a compelling fact-based story of how the company is currently performing. To compare NovoCure Limited's metrics versus it's peers make sure to run our peer analysis tool.

Valuation Metrics

Metric Value Ranking among Peers
PE -1.00 12/15
PS 4.98 8/15
PB 0.00 15/15
PC -1.00 15/15
Liabilities to Equity 2.39 3/15
ROA -1.00 15/15
ROE -0.42 14/15
Current Ratio 0.00 15/15
Quick Ratio 0.00 15/15
Long Term Debt to Equity 0.00 14/15
Debt to Equity 0.24 10/15
Burn Rate 0.00 7/15
Cash to Cap 0.00 15/15
CCR 0.01 13/15
EV to EBITDA -92.37 12/15
EV to Revenue 5.13 7/15

Company Details

NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of Optune for the treatment of a variety of solid tumors. The company markets Optune and Optune Lua, a Tumor Treating Fields (TTFields) devices for use as a monotherapy treatment for adult patients with glioblastoma. It is also developing products for brain metastases, non-small cell lung cancer, pancreatic cancer, gastric cancer, ovarian cancer, liver cancer, and malignant pleural mesothelioma. The company markets its products in the European Union, the United Kingdom, Japan, and internationally. It has a clinical study collaboration agreement with MSD to study TTFields together with KEYNOTE, an anti-PD-1 therapy; and a strategic collaboration with Zai Lab (Shanghai) Co., Ltd. to commercialize its products in Greater China and establishes a development partnership intended to accelerate the development of TTFields in multiple solid tumor cancer indications. NovoCure Limited was incorporated in 2000 and is based in Saint Helier, Jersey.

CEO: Mr. Asaf Danziger

Website: https://www.novocure.com

Address: Forum, NO. 4 Grenville Street Saint Helier,

Exchange: NASDAQ Global Select

Industry: Medical Instruments & Supplies

NovoCure Limited Peer Analysis


A useful and more reliable way of seeing the health of a company is to compare it to other companies operating in the same sector. Below is our list of companies which we rank are the closest peers to NovoCure Limited. If you feel that peers should be added or removed from this list please contact us. To run an in-depth peer analysis which compares many financial metrics click on the link below.

Stock Ticker Market Cap
LivaNova PLC LIVN $2.7 Billion
Insulet Corporation PODD $18.8 Billion
Masimo Corporation MASI $9.1 Billion
Globus Medical, Inc. GMED $11.3 Billion
iRhythm Technologies, Inc. IRTC $2.5 Billion
Integer Holdings Corporation ITGR $4.7 Billion
Penumbra, Inc. PEN $9.3 Billion
CONMED Corporation CNMD $2.2 Billion
Heska Corporation HSKA $1.3 Billion
Inspire Medical Systems, Inc. INSP $5.7 Billion
InMode Ltd. INMD $1.5 Billion
ShockWave Medical, Inc. SWAV $12.6 Billion
TransMedics Group, Inc. TMDX $2.2 Billion
Inari Medical, Inc. NARI $3.0 Billion
Run Peer Analysis
Income Statement
Balance Sheet
Cash Flow Statement
NVCR Income Statements
Quarter Year Revenue Earnings
Q3 2024 $ 155.1 Million -$30.6 Million
Q2 2024 $ 150.4 Million -$33.4 Million
Q1 2024 $ 138.5 Million -$38.8 Million
Q4 2023 $ 133.8 Million -$47.1 Million
Q3 2023 $ 127.3 Million -$49.5 Million
Q2 2023 $ 126.1 Million -$57.4 Million
Q1 2023 $ 122.2 Million -$53.1 Million
Q4 2022 $ 128.4 Million -$37.3 Million

View All

NVCR Balance Sheets
Quarter Year Cash & Equivalents Total Assets Total Debt Total Equity
Q3 2024 $0 $0 $86.4 Million $360.8 Million
Q2 2024 $168.4 Million $1.2 Billion $675.2 Million $361.8 Million
Q1 2024 $453.8 Million $1.1 Billion $595.3 Million $359.4 Million
Q4 2023 $240.8 Million $1.1 Billion $596.2 Million $362.5 Million
Q3 2023 $154.9 Million $1.1 Billion $590.0 Million $393.7 Million
Q2 2023 $157.0 Million $1.2 Billion $587.5 Million $415.7 Million
Q1 2023 $186.0 Million $1.2 Billion $586.3 Million $432.1 Million
Q4 2022 $115.3 Million $1.2 Billion $584.3 Million $441.2 Million

View All

NVCR Cash Flow Statements
Quarter Year freeCashFlow capitalExpenditure netChangeInCash
Q3 2024 -$307,000 -$10.7 Million $20.8 Million
Q2 2024 -$13.2 Million -$11.4 Million -$288.9 Million
Q1 2024 -$43.4 Million -$11.8 Million $214.8 Million
Q4 2023 -$21.4 Million -$6.8 Million $86.1 Million
Q3 2023 -$26.6 Million -$7.3 Million -$982,000
Q2 2023 -$29.7 Million -$6.9 Million -$29.1 Million
Q1 2023 -$22.8 Million -$6.1 Million $70.8 Million
Q4 2022 -$10.1 Million -$6.4 Million -$128.2 Million

View All

Cookies

We use cookies to offer a better browsing experience. Cookies enhance site navigation, analyze site usage, and assist in our marketing efforts. By clicking Accept. you agree to the storing of cookies on your device. To refuse all non-required cookies, click on Decline.

Accept View Terms & Conditions